Swiss National Bank Acquires 290,100 Shares of Boston Scientific Corporation $BSX

Swiss National Bank lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 7.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,350,600 shares of the medical equipment provider’s stock after purchasing an additional 290,100 shares during the period. Swiss National Bank’s holdings in Boston Scientific were worth $273,000,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $29,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 9,800 shares of company stock worth $554,012 in the last quarter. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BSX. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research report on Thursday, April 23rd. Stifel Nicolaus lowered their price target on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, June 25th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $79.84.

Boston Scientific Stock Down 1.5%

Shares of NYSE:BSX opened at $43.95 on Friday. The company has a market capitalization of $65.33 billion, a price-to-earnings ratio of 18.39, a P/E/G ratio of 0.84 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business’s 50-day moving average is $48.18 and its 200-day moving average is $65.87. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the company earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.35 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.